Palifermin: profile and news

Kepivance™ Improves Patient-Assessed Oral Mucositis Following ... Apr 21, 2006
The results of patient evaluations of a phase III randomized trial of Kepivance™ (palifermin, epidermal growth factor) for the prevention of oral mucositis ... - Cancer Consultants (press release),

Other information

Indication
For treatment of mucositis (mouth sores)

Pharmacology
Used in the prevention or treatment of oral mucoscitis (mouth ulcers arising from chemotherapy), Kepivance binds to the human keratinocyte growth factor (KGF) receptor on buccal cell surfaces. Kepivance acts as both a cell growth and survival factor by stimulating epithelial cell proliferation, differentiation, and migration around the tongue and mouth. The KGF receptor is found on many tissues particularly around the tongue, esophagus, salivary gland and other gastro-intestinal tract organs.

Mechanism Of Action
Kepivance binds to the human keratinocyte growth factor (KGF) receptor found on buccal cell surfaces. The binding activates a Ras-MapK (Map kinase) signaling pathway which leads to the transcriptional activation of many proteins important for cell growth and survival.

Drug Category
Antimucositis Agents

Brand Names/Synonyms
Keratinocyte growth factor precursor;KGF;Fibroblast growth factor- 7;FGF-7;HBGF-7; Kepivance (Amgen Inc)

Dosage Forms
Not Available

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
Human keratinocyte growth factor

Chemical Formula
C721H1142N202O204S9

Half Life
Not Available

Drug Type
Approved Drug

# Accession No
BIOD00042

CAS Registry Number
162394-19-6